Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics Ltd is positioned for a positive outlook due to the significant clinical efficacy of its lead product, Allocetra, which demonstrated statistically meaningful improvements in pain and function among patients aged 60 and older, a demographic that constitutes a substantial portion of the osteoarthritis market. The company's ability to capitalize on elevated trading volumes, supported by an existing at-the-market (ATM) facility, is expected to enhance liquidity and sustain operational momentum for the ongoing development of Allocetra. Furthermore, Allocetra's favorable safety profile and ongoing exploratory studies into additional applications underline its potential for broadening market opportunities, contributing to an optimistic outlook for investor confidence and financial performance.

Bears say

Enlivex Therapeutics Ltd faces significant risks that contribute to a negative outlook on its stock, including the potential for adverse clinical trial results and challenges in securing timely approvals for its lead product, Allocetra. Additional concerns involve the company's ability to establish partnerships for advancing its applications, as well as uncertainties surrounding market penetration and liquidity issues in its RAIN token strategy. The disconnect between clinical advancements and market perception further complicates the situation, prompting a reevaluation of the company's approach to capital access and investor engagement.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.